Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma

David G. Mummy; Stanley J. Kruger; Wei Zha; Ronald L. Sorkness; Nizar N. Jarjour; Mark L. Schiebler; Loren C. Denlinger; Michael D. Evans; Sean B. Fain

doi:10.1016/j.jaci.2017.10.016

Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma

David G. Mummy
, Stanley J. Kruger
, Wei Zha
, Ronald L. Sorkness
, Nizar N. Jarjour
, Mark L. Schiebler
, Loren C. Denlinger
, Michael D. Evans
, Sean B. Fain

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	1140-1141.e4
Journal	Journal of Allergy and Clinical Immunology
Volume	141
Issue number	3
DOIs	https://doi.org/10.1016/j.jaci.2017.10.016
State	Published - Mar 2018
Externally published	Yes

Bibliographical note

Funding Information:
This work was supported by the National Institutes of Health (grant nos. R01 HL080412 , R01 HL069116 , U10 HL109168 , and UL1TR000427 ), GE Healthcare, and the Wisconsin Alumni Research Foundation Technology Training Research Assistantship.

Funding Information:
Disclosure of potential conflict of interest: D. G. Mummy's institution received grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) (grant no. U01 HL109168), GE Healthcare, and Wisconsin Alumni Research Foundation for this work. R. L. Sorkness' institution received a grant from the NIH-NHLBI for this work and other works. N. N. Jarjour's institution received a grant from the NIH (grant no. U10HL109168 to N.N.J.) for this work; he personally received consultancy fees from Teva Pharmaceuticals, Astrazeneca, and Daiichi Sankyo; the institution received grants P01HL088584 (N.N.J.), 1R01HL109031-01 (Fiore), U10 HL098090 (Lemanske, R.L.S.), UL1TR000427 (Drezner), R01HL123284 (Busse), and RFA-HL-17-009 (L.C.D/N.N.J.) for other works. M. L. Schiebler's institution received a grant, support for travel, fees for review activities, payments for reviewing/writing this manuscript, and provision of writing assistance from the NHLBI/NIH for this work; the institution received grants, patents, royalties, payment for development of educational presentations, stock/stock options, and travel accommodations from the NHLBI/NIH for other works. L. C. Denlinger's institution received a grant from the NIH for this work; he personally received consultancy fees from GSK and Novartis; his institution received grants from the NIH for other works. M. D. Evans' institution received a grant from the NIH for this work. S. B. Fain's institution received a grant from the NIH/NHLBI (grant no. U01 HL109168) and from GE Healthcare for this work; he personally received consultancy fees from GE Healthcare. The rest of the authors declare that they have no relevant conflicts of interest. Letter to the Editor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1016/j.jaci.2017.10.016

Find It

Find It at U of M Libraries

Cite this

@article{e3db82c445e54cef9d0ee18cf3975f41,

title = "Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma",

author = "Mummy, \{David G.\} and Kruger, \{Stanley J.\} and Wei Zha and Sorkness, \{Ronald L.\} and Jarjour, \{Nizar N.\} and Schiebler, \{Mark L.\} and Denlinger, \{Loren C.\} and Evans, \{Michael D.\} and Fain, \{Sean B.\}",

note = "Funding Information: This work was supported by the National Institutes of Health (grant nos. R01 HL080412 , R01 HL069116 , U10 HL109168 , and UL1TR000427 ), GE Healthcare, and the Wisconsin Alumni Research Foundation Technology Training Research Assistantship. Funding Information: Disclosure of potential conflict of interest: D. G. Mummy's institution received grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) (grant no. U01 HL109168), GE Healthcare, and Wisconsin Alumni Research Foundation for this work. R. L. Sorkness' institution received a grant from the NIH-NHLBI for this work and other works. N. N. Jarjour's institution received a grant from the NIH (grant no. U10HL109168 to N.N.J.) for this work; he personally received consultancy fees from Teva Pharmaceuticals, Astrazeneca, and Daiichi Sankyo; the institution received grants P01HL088584 (N.N.J.), 1R01HL109031-01 (Fiore), U10 HL098090 (Lemanske, R.L.S.), UL1TR000427 (Drezner), R01HL123284 (Busse), and RFA-HL-17-009 (L.C.D/N.N.J.) for other works. M. L. Schiebler's institution received a grant, support for travel, fees for review activities, payments for reviewing/writing this manuscript, and provision of writing assistance from the NHLBI/NIH for this work; the institution received grants, patents, royalties, payment for development of educational presentations, stock/stock options, and travel accommodations from the NHLBI/NIH for other works. L. C. Denlinger's institution received a grant from the NIH for this work; he personally received consultancy fees from GSK and Novartis; his institution received grants from the NIH for other works. M. D. Evans' institution received a grant from the NIH for this work. S. B. Fain's institution received a grant from the NIH/NHLBI (grant no. U01 HL109168) and from GE Healthcare for this work; he personally received consultancy fees from GE Healthcare. The rest of the authors declare that they have no relevant conflicts of interest. Letter to the Editor ",

year = "2018",

month = mar,

doi = "10.1016/j.jaci.2017.10.016",

language = "English (US)",

volume = "141",

pages = "1140--1141.e4",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma

AU - Mummy, David G.

AU - Kruger, Stanley J.

AU - Zha, Wei

AU - Sorkness, Ronald L.

AU - Jarjour, Nizar N.

AU - Schiebler, Mark L.

AU - Denlinger, Loren C.

AU - Evans, Michael D.

AU - Fain, Sean B.

N1 - Funding Information: This work was supported by the National Institutes of Health (grant nos. R01 HL080412 , R01 HL069116 , U10 HL109168 , and UL1TR000427 ), GE Healthcare, and the Wisconsin Alumni Research Foundation Technology Training Research Assistantship. Funding Information: Disclosure of potential conflict of interest: D. G. Mummy's institution received grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) (grant no. U01 HL109168), GE Healthcare, and Wisconsin Alumni Research Foundation for this work. R. L. Sorkness' institution received a grant from the NIH-NHLBI for this work and other works. N. N. Jarjour's institution received a grant from the NIH (grant no. U10HL109168 to N.N.J.) for this work; he personally received consultancy fees from Teva Pharmaceuticals, Astrazeneca, and Daiichi Sankyo; the institution received grants P01HL088584 (N.N.J.), 1R01HL109031-01 (Fiore), U10 HL098090 (Lemanske, R.L.S.), UL1TR000427 (Drezner), R01HL123284 (Busse), and RFA-HL-17-009 (L.C.D/N.N.J.) for other works. M. L. Schiebler's institution received a grant, support for travel, fees for review activities, payments for reviewing/writing this manuscript, and provision of writing assistance from the NHLBI/NIH for this work; the institution received grants, patents, royalties, payment for development of educational presentations, stock/stock options, and travel accommodations from the NHLBI/NIH for other works. L. C. Denlinger's institution received a grant from the NIH for this work; he personally received consultancy fees from GSK and Novartis; his institution received grants from the NIH for other works. M. D. Evans' institution received a grant from the NIH for this work. S. B. Fain's institution received a grant from the NIH/NHLBI (grant no. U01 HL109168) and from GE Healthcare for this work; he personally received consultancy fees from GE Healthcare. The rest of the authors declare that they have no relevant conflicts of interest. Letter to the Editor

PY - 2018/3

Y1 - 2018/3

UR - https://www.scopus.com/pages/publications/85037736835

UR - https://www.scopus.com/pages/publications/85037736835#tab=citedBy

U2 - 10.1016/j.jaci.2017.10.016

DO - 10.1016/j.jaci.2017.10.016

M3 - Article

C2 - 29129582

AN - SCOPUS:85037736835

SN - 0091-6749

VL - 141

SP - 1140-1141.e4

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 3

ER -

Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Cite this